Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Brain Neoplasms 4Neuroblastoma 3Recurrence 2Melanoma 2Medulloblastoma 2Glioblastoma 2Neoplasm Metastasis 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 2fludarabine 2Radiosurgery 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1regorafenib 1pazopanib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1ibrutinib 1grapiprant 1fludarabine phosphate 1famitinib 1encorafenib 1copanlisib 1cemiplimab 1capivasertib 1camrelizumab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disease Progression × TPI-287 × Clear all
NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡